Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as ShK-186
dalazatide · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 30ug dalazatide | EXPERIMENTAL | 12 subjects, 10 given active agent and 2 given placebo by subcutaneous injection twice weekly for 4 weeks. |
| 60ug dalazatide | EXPERIMENTAL | 12 subjects, 10 given active agent and 2 given placebo by subcutaneous injection twice weekly for 4 weeks. |
| Name | Type | Description |
|---|---|---|
| dalazatide | DRUG | Subcutaneous injection twice per week for a total of 9 doses, followed by four weeks of follow-up. |
| placebo | DRUG | placebo, Subcutaneous injection twice per week for a total of 9 doses |
Inclusion Criteria: 1. Adult male and female subjects, ages 18-65; 2. Active plaque psoriasis with ≥3% BSA involved; 3. An adequate number of vulgar psoriatic plaques of at least 2 cm X 2 cm with Target Lesion Investigator Global Assessment scores \>3, that are not located on the face, scalp, groin...
Dalazatide is an investigational small molecule being developed for the treatment of plaque psoriasis, a chronic inflammatory skin condition. It has been studied in a Phase 1 clinical trial in adults with active plaque psoriasis. Dalazatide is not yet approved for any indication and remains in clinical development.
Dalazatide is being developed by TuHURA Biosciences, Inc., a biopharmaceutical company that trades under the ticker symbol HURA. The company is responsible for the clinical development of dalazatide in plaque psoriasis.
Dalazatide is in Phase 1 clinical development. It has completed one Phase 1 trial in plaque psoriasis. There are currently no active trials of dalazatide. The drug is investigational and has not been approved by the FDA or any regulatory agency.
Dalazatide has been evaluated in a single completed Phase 1 trial, NCT02435342, titled "A 4 Week Study of the Safety, Tolerability, and Pharmacodynamics of ShK-186 (Dalazatide) in Active Plaque Psoriasis." The trial enrolled 24 participants in Canada and was randomized, double-blind, and controlled.
Yes, dalazatide is also known as ShK-186. The Phase 1 trial NCT02435342 refers to the drug as ShK-186 (Dalazatide), confirming that both names identify the same investigational compound being developed for plaque psoriasis.